Cytokinetics, Inc. Stock Nasdaq
Stocks
US23282W1009
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 10.47B 9.1B 8.47B 7.78B 14.69B 1T 14.92B 99.88B 39.2B 498B 39.33B 38.46B 1,669B | P/E 2026 * |
-12.1x | P/E 2027 * | -16.5x |
|---|---|---|---|---|---|
| Enterprise Value | 9.89B 8.59B 8B 7.34B 13.87B 944B 14.08B 94.29B 37B 470B 37.13B 36.31B 1,575B | EV / Sales 2026 * |
87.6x | EV / Sales 2027 * | 25.1x |
| Free-Float |
98.24% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytokinetics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 62 | 2006-12-31 |
Sung Lee
DFI | Director of Finance/CFO | 55 | 2024-05-07 |
| Chief Administrative Officer | 57 | 2025-11-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Blum
BRD | Director/Board Member | 62 | 2006-12-31 |
John Henderson
CHM | Chairman | 81 | 2022-04-07 |
Wendell Wierenga
BRD | Director/Board Member | 78 | 2011-02-08 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.35% | +2.74% | +38.10% | +71.29% | 56.54B | |
| -0.21% | -7.38% | +27.52% | +61.15% | 53.6B | |
| -2.44% | +1.40% | -15.61% | -15.45% | 22.91B | |
| -2.85% | -7.78% | -9.28% | +345.55% | 21.37B | |
| +2.49% | -0.92% | +23.57% | -13.14% | 20.27B | |
| +0.79% | -1.06% | +33.99% | -31.95% | 17.56B | |
| +0.58% | -5.88% | +19.40% | +527.50% | 14.75B | |
| +3.41% | -6.61% | +162.81% | +278.22% | 13.53B | |
| -5.25% | -4.23% | +42.32% | +170.15% | 13.33B | |
| Average | -0.13% | -3.79% | +35.87% | +154.81% | 25.98B | |
| Weighted average by Cap. | +0.23% | -2.96% | +30.79% | +116.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 113M 98.12M 91.33M 83.85M 158M 10.77B 161M 1.08B 422M 5.36B 424M 415M 17.99B | 393M 342M 318M 292M 552M 37.55B 560M 3.75B 1.47B 18.7B 1.48B 1.44B 62.69B |
| Net income | -796M -692M -644M -591M -1.12B -76B -1.13B -7.59B -2.98B -37.84B -2.99B -2.92B -127B | -655M -569M -530M -486M -918M -62.5B -933M -6.24B -2.45B -31.11B -2.46B -2.4B -104B |
| Net Debt | -586M -510M -474M -436M -823M -55.97B -835M -5.59B -2.19B -27.86B -2.2B -2.15B -93.43B | -606M -527M -490M -450M -850M -57.82B -863M -5.78B -2.27B -28.78B -2.27B -2.22B -96.52B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
